NantHealth (DB:NEL0) - Cours de l'action, nouvelles et analyse

NEL0 Aperçu des actions

Operates as a healthcare IT company in the United States, Canada, and the United Kingdom. Plus de détails

NEL0 analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	2/6
Dividendes	0/6

Analyse des risques

Capitaux propres négatifs

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Les actions sont très illiquides

N'a pas de capitalisation boursière significative ( €13M )

NantHealth, Inc. Concurrents

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€41.4m

CompuGroup Medical SE KGaA

XTRA:COP

€786.4m

Geratherm Medical

XTRA:GME

€21.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour NantHealth
Historique des cours de bourse
Prix actuel de l'action	US$0.26
Plus haut sur 52 semaines	US$5.17
Plus bas sur 52 semaines	US$0.20
Bêta	1.64
1Variation sur 1 mois	0%
Variation sur 3 mois	0%
Variation sur 1 an	-93.60%
3Variation sur 3 ans	-99.06%
Variation sur 5 ans	-98.24%
Évolution depuis l'introduction en bourse	-99.86%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	NEL0	DE Healthcare Services	DE Marché
7D	0%	2.3%	0.8%
1Y	-93.6%	-31.3%	9.1%

Rendement vs Industrie: NEL0 a sous-performé le secteur German Healthcare Services qui a rapporté -31.3 % au cours de l'année écoulée.

Rendement vs marché: NEL0 a sous-performé le marché German qui a rapporté 9.1 % au cours de l'année écoulée.

Volatilité des prix

Is NEL0's price volatile compared to industry and market?
NEL0 volatility
NEL0 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de NEL0 a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de NEL0 au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2010	373	Rao Naseem	nanthealth.com

NantHealth, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de NantHealth se comparent-ils à sa capitalisation boursière ?
NEL0 statistiques fondamentales
Capitalisation boursière	€11.54m
Bénéfices(TTM)	-€63.09m
Recettes(TTM)	€62.54m

0.2x

Ratio P/S

-0.2x

Ratio P/E

Le site NEL0 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
NEL0 compte de résultat (TTM)
Recettes	US$68.44m
Coût des recettes	US$23.74m
Marge brute	US$44.69m
Autres dépenses	US$113.74m
Les revenus	-US$69.04m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-2.51
Marge brute	65.31%
Marge bénéficiaire nette	-100.89%
Ratio dettes/capitaux propres	-111.3%

Quelles ont été les performances à long terme de NEL0?

Voir les performances historiques et les comparaisons

NEL0 Aperçu des actions

Analyse des risques

NantHealth, Inc. Concurrents

XTRA:M3V

€44.4m

XTRA:AJ91

€41.4m

XTRA:COP

€786.4m

XTRA:GME

€21.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

NantHealth, Inc. Résumé des fondamentaux